MUMBAI, India, Sept. 22 -- Intellectual Property India has published a patent application (202617071686 A) filed by Orionis Biosciences, Inc. on June 09, 2026, for Pd-L1-Based Chimeric Protein Formulations.
Inventors include Kley, Nikolai; Depla, Erik; and Van Lysebetten, Dorien.
The application for the patent was published on September 18, 2026, under issue no. 38/2026.
Abstract: The present application provides, in part, pharmaceutical formulations of PD-L1 -based chimeric proteins and protein complexes and uses thereof. In some embodiments, it includes a pharmaceutical composition or formulation comprising (a) a Programmed death-ligand 1 (PD-L l)-based chimeric protein or chimeric protein complex comprising (i) a targeting moiety that specifically binds to PD-L1, (ii) a modified human IFNa2, and (iii) a modified Fe domain; (b) at least one pharmaceutically acceptable buffering agent comprising a histidine buffer (e.g., at a concentration of at least about 10 mM to about 30 mM); (c) at least one pharmaceutically acceptable excipient comprising a surfactant; and (d) at least one pharmaceutically acceptable excipient comprising a tonicifier.
Disclaimer: Curated by HT Syndication.
